Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?
作者信息
Goldberg Sarah B, Herbst Roy S
机构信息
Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut.
Department of Medicine (Medical Oncology) and Pharmacology, Yale School of Medicine, New Haven, Connecticut.
出版信息
Cancer. 2018 Dec 15;124(24):4592-4596. doi: 10.1002/cncr.31681. Epub 2018 Nov 1.
Abstract
摘要
相似文献
1
Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?
Cancer. 2018 Dec 15;124(24):4592-4596. doi: 10.1002/cncr.31681. Epub 2018 Nov 1.
2
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
3
Advanced non-small cell lung cancer - treatment with Pembrolizumab.
Rev Assoc Med Bras (1992). 2020 Mar;66(3):256. doi: 10.1590/1806-9282.66.3.256.
4
Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.
J Oncol Pract. 2018 Sep;14(9):569-571. doi: 10.1200/JOP.18.00127. Epub 2018 Jul 25.
5
Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Clin Lung Cancer. 2017 Sep;18(5):444-459.e1. doi: 10.1016/j.cllc.2017.02.001. Epub 2017 Feb 16.
6
Atezolizumab and Its Many Uses.
Oncology (Williston Park). 2019 Aug 23;33(8):683723.
7
Immunotherapy for non-small cell lung cancer.
JAAPA. 2019 Sep;32(9):37-42. doi: 10.1097/01.JAA.0000569792.99069.e6.
8
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Lung Cancer. 2019 Jan;127:44-52. doi: 10.1016/j.lungcan.2018.11.008. Epub 2018 Nov 23.
9
Adjuvant Therapy in Patients With Completely Resected Non-small-cell Lung Cancer: Current Status and Perspectives.
Clin Lung Cancer. 2019 Jan;20(1):1-6. doi: 10.1016/j.cllc.2018.09.016. Epub 2018 Sep 24.
10
Platinum-based doublet chemotherapy plus bevacizumab without bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC).
Anticancer Res. 2013 Aug;33(8):3275-8.
引用本文的文献
1
Efficacy of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.
Transl Lung Cancer Res. 2024 Sep 30;13(9):2212-2221. doi: 10.21037/tlcr-24-263. Epub 2024 Sep 12.
2
Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90.
Clin Lung Cancer. 2023 May;24(3):235-243. doi: 10.1016/j.cllc.2023.02.007. Epub 2023 Mar 1.
3
Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors.
Clin Cancer Res. 2022 Jan 15;28(2):368-377. doi: 10.1158/1078-0432.CCR-21-2275.
4
First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis.
Cancer Immunol Immunother. 2022 Jun;71(6):1345-1355. doi: 10.1007/s00262-021-03089-x. Epub 2021 Oct 16.
5
Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions.
Cancers (Basel). 2021 Jul 7;13(14):3407. doi: 10.3390/cancers13143407.
6
Molecular Profiling of Exceptional Responders to Cancer Therapy.
Oncologist. 2021 Mar;26(3):186-195. doi: 10.1002/onco.13600. Epub 2020 Nov 28.
本文引用的文献
1
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
2
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
3
The biology and management of non-small cell lung cancer.
Nature. 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183.
4
Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.
Cell. 2017 Dec 14;171(7):1678-1691.e13. doi: 10.1016/j.cell.2017.11.009.
5
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
Cancer Discov. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 2017 Oct 12.
6
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.
7
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
8
Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.
Cancer Res. 2014 Jul 1;74(13):3441-53. doi: 10.1158/0008-5472.CAN-13-3596. Epub 2014 Apr 29.
9
Effects of conventional therapeutic interventions on the number and function of regulatory T cells.
Oncoimmunology. 2013 Oct 1;2(10):e27025. doi: 10.4161/onci.27025.
10
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
J Clin Oncol. 2013 Aug 10;31(23):2895-902. doi: 10.1200/JCO.2012.47.1102. Epub 2013 Jul 8.
Zotero 插件